Abstract. Regulatory agencies, industry, and academia have acknowledged that in vitro assessments serve a role in establishing bioequivalence for second-entry drug product approvals as well as innovator postapproval drug product changes. For orally inhaled respiratory products (OIPs), the issues of correctly analyzing in vitro data and interpreting the results within the broader context of therapeutic equivalence have garnered significant attention. One of the recommended statistical tests for in vitro data is the population bioequivalence method (PBE). The current literature for assessing the PBE statistical approach for in vitro data assumes a log normal distribution. This paper focuses on an assessment of that assumption for in vitro delivered dose. Concepts in development of a statistical model are presented. The PBE criterion and hypotheses are written for the case when data follows a normal distribution, rather than log normal. Results of a simulation study are reported, characterizing the performance of the PBE approach when data are expected to be normally distributed, rather than log normal. In these cases, decisions using the PBE approach are not consistent for the same absolute mean difference that the test product is from the reference product. A conclusion of inequivalency will occur more often if the test product dose is lower than the reference product for the same deviation from target. These features suggest that more research is needed for statistical equivalency approaches for in vitro data.
INTRODUCTION
The determination of bioequivalence for orally inhaled products has been a topic of interest in the pharmaceutical industry in the last decade. Concepts related to bioequivalence and bioavailability are defined in the Federal Food, Drug, and Cosmetic Act in 21 USC 355(j) (8) "The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study."
Bioequivalence is assessed from the comparison of bioavailability between two drug products. In this same guidance document, bioavailability was defined as:
"the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of action."
Bioequivalence and bioavailability are then used to establish therapeutic equivalence. As Lee et al. stated, demonstrating bioequivalence for orally inhaled products and nasal sprays is challenging because of the "incomplete understanding of the relevance of drug concentration in blood or plasma to equivalence in drug delivery to the local site(s) of action" (2) . This has influenced the FDA to adopt an aggregate "weight of evidence" approach, based on demonstrating equivalent in vitro performance through in vitro studies, equivalent systemic exposure through pharmacokinetic or pharmacodynamic studies, and equivalent local action through clinical endpoint studies (3) . This paper focuses on the topic of demonstrating equivalent in vitro performance, particularly the equivalence of delivered dose.
Draft guidelines for equivalency of in vitro data were issued as part of the 1999 guidance document entitled, Guidance for Industry: Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action (4) . Analysis approaches for different in vitro tests, labeled profile and non-profile, were introduced. Examples of nonprofile tests included content through container life, droplet size distribution, spray pattern, and drug in small particles. Profile analyses were related to particle size distribution as measured through cascade impaction. The recommended statistical methodology for assessing equivalence in four of the in vitro tests was the population bioequivalence criterion (PBE). In 2003, this draft guidance document was updated. The statistical appendices, to contain details for the recommended analysis procedures, were listed in the updated document, but were not issued. More recently, at the GPhA/FDA 2012 Fall Technical Conference, the Office of Generic Drugs presented recommendations for implementing the PBE analysis for in vitro data as well as scientific and regulatory considerations for bioequivalence of dry powder inhalers (5) . Recommendations from this conference were then reflected in recent product-specific guidance for budesonide and albuterol sulfate (6, 7) .
The European Medicines Agency states that limits of ±15% should be applied to the mean of the delivered dose when establishing drug product specifications. Comparative in vitro data must be provided. Exact statistical methodology is not detailed (8) .
The current literature for assessing the PBE statistical approach for equivalence of in vitro data assumes that the log normal distribution is, fundamentally, the correct statistical model to describe the data collected. This is the case for both Chow et al.'s article in 2003, in which the statistical model and PBE methodology was extended to include replication per unit, and Chiu et al.'s article in 2010, in which a nested random effects model was proposed (9, 10) . This paper focuses on an assessment of that assumption for in vitro delivered dose and the practical impact to decision making when that assumption is not appropriate.
In the Methods section, concepts regarding development of a statistical model are introduced and statements regarding the processes that generated the data are reviewed under different model assumptions. This section contrasts the differences between processes that generate in vivo and in vitro data to highlight why consideration of different statistical models is warranted. Also in this section, the PBE criterion and associated hypotheses, applied to log-transformed data, are expressed as a function of parameters in the original data metric when data follow a normal distribution. The forms of those hypothesis statements, in the original metric, then establish the basis of the work presented in the Results section.
In the Results section, both a graphical review of the PBE as a function of the population parameters in the original metric and the results of a simulation study are presented and discussed. The simulation study was designed to better understand the practical impact of applying the PBE to log-transformed data when the data are expected to follow a normal distribution in the original metric.
This paper presents results of research focused on one of the primary statistical methods for equivalency assessment for in vitro data. A subsequent paper will follow that presents different population requirements, representing statements of equivalency between two data distributions, and the performance properties of different statistical methodologies for those population statements.
Taken together, these papers serve to provide an initial structure in how to consider an appropriate statistical model for in vitro data and then, how to phrase equivalency statements as statistical hypothesis statements of the population parameters, for which the risks of different statistical methods and decision rules can then be assessed. This overall process can be extended into more complicated models for in vitro data or extended to other in vitro tests for which an assessment of statistical equivalence is required.
METHODS
In this section, a review of statistical models for delivered dose is conducted. Contrasts are made between the processes generating in vivo and in vitro data to highlight why consideration of different statistical models is warranted. An assessment of the PBE criterion as a function of parameters in the original data metric is presented.
Review of Statistical Models for In Vitro Delivered Dose
In vitro delivered dose is a measure of drug content available to the patient in each dose of drug product. The data are obtained from analytical testing implemented in the laboratory on units sampled from the final drug product batch and are typically reported as a percentage of the label claim dose. From each batch of drug product, a pre-defined number of units are sampled and a pre-determined number of doses are measured. Regulatory specifications are imposed on the mean delivered dose and/or on a function of individual values, depending on the intended commercial market. The registered specifications for dose, according to ICH Q6, are "critical quality standards that are proposed and justified by the manufacturer and approved by regulatory authorities as condition of approval" to be released to market (11) . The detailed sampling and testing scheme that defines how the units are selected from the batch, how the analytical method is conducted, and how the product quality is demonstrated can vary. Guidance documents, regulations, and compendial standards exist to assist applicants in the development process (12-18).
A critical aspect of applying a statistical methodology for decision making is determining the statistical model and the nature of the error distribution. As with in vivo bioequivalence, it makes more sense to base decisions on the nature of the error distribution from first principles, rather than p-values from goodness-of-fit approaches.
The next sections review statements about delivered dose and the processes that generate the data. The intent is to assess the appropriateness of a statistical model from first principles. We will then show, using simulation, the impact of applying a log normal transformation to in vitro data when a normal distribution is more appropriate.
Normal Distribution Properties for In Vitro Delivered Dose
Manufacturing processes are developed and validated to deliver the label claim dose to a patient and to ensure continuing drug product quality and performance. Analytical methods, intended to measure attributes of the units produced from these manufacturing processes, are developed to provide an accurate quantification of the chemical, physical, biological, or microbiological attributes of the units. Sources of variation, however, are acknowledged to exist in any successful manufacturing or analytical testing process (19) (20) (21) (22) (23) (24) (25) (26) (27) .
Dose measurements often vary around the target label claim value in a symmetric manner, as reflected in the compendial specifications for delivered dose in USP Chapter 601 (17) . As outlined in the process validation guidance, understanding variation is the essence of a successful validation and manufacturing program throughout the lifecycle of the product. As stated in this guidance, manufacturers should "understand the sources of variation, detect the presence and degree of variation, and understand the impact of variation on the process and ultimately on product attributes" (24) .
Variation, therefore, is an inherent component of manufacturing processes and analytical testing procedures. For orally inhaled drug products, variability can be introduced due to raw material differences, manufacturing variability at different unit operation stages (e.g., micronization), blend or concentration variation, equipment performance variability, filling or mixing variation, device or component variability, and finally, analytical testing and analytical equipment variability.
In manufacturing, variation introduced from one-unit operation can often follow through other processes and result in variation in the end product. For example, uniformity issues in concentration of the active pharmaceutical ingredient could be introduced during blending, and during the next unit operation, the fill weight variation would not be impacted and the uniformity problems would, then, carry through until final drug product testing and release. Analytical variability or device variability is not expected to depend or be relative to data from a previous unit operation. In this way, the sources of variation in the final drug product quality are additive, rather than multiplicative (28) . Additive sources of variation are more typically modeled by a normal distribution. This is also reflected in the nature and form of the specifications as well.
In its simplest form, the statistical model that describes data in which results vary around a target value, deviations from target are expected to occur additively and in a symmetric manner, and variation is independent of the mean is the normal distribution. In its simplest form, this model is written as: The model above does not directly estimate components of variation due to batch differences or variation in delivered dose within a device or unit, sampled from a particular batch. The basic statistical model above can be extended to include those components, and therefore, the total variation would be a sum of factors that represent batch variation, unit or device variation within a batch, and remaining unexplained manufacturing and testing variation.
The normality assumption of delivered dose was further supported by an analysis of industry data from the database collected by the Inhalation Technology Focus Group (ITFG) of the American Association of Pharmaceutical Scientists (AAPS) in collaboration with the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS) (28) .
This analysis showed that the overall distribution of delivered dose data was symmetrical and that, after standardization, the fit to a normal distribution was excellent. This was the case even into the tails of the distribution. The ITFG/ IPAC-RS DCU database contained data for 80 products with a total of 46,816 individual determinations. In order to pool all the data from different products, all products were standardized to a mean of zero and a standard deviation of unity, in order to show the general shape of the distribution. The histogram of these data presented in the article is replicated in Fig. 1 . These data show that the log transformation is not needed to achieve normality.
Beyond the overall normality assessment for all products in this database, normality was also assessed separately for individual product types (29) . Data from a CFC metered dose inhaler (MDI), an HFA MDI, a pre-metered dry powder inhaler (DPI), a device-metered DPI, and a non-pressurized nasal spray were analyzed and it was concluded that a normality assumption was a better fit to the data when analyzed by product type.
Non-normality of the data was noted in this report to potentially occur, resulting in multimodal or skewed distributions (29) . Multimodal distributions are often mixtures of two normal distributions that could occur, for example, due to fill weight changes during a batch. Skewed distributions could occur if a multidose product with a through container life trend shows different variability for beginning and end doses. However, both these situations actually reflect a model in which the error component may be normally distributed but the mean component may need to be expressed in a more complicated form, incorporating a known bias or trend. From a fundamental assessment that the factors which influence product variability are additive as well as from a practical assessment of raw data and the nature of defined specifications, the normality assumption and statistical model seems the most appropriate, underlying statistical model to describe delivered dose data for orally inhaled drug products.
Log Normal Distribution Properties for PK Data
This section reviews the principles by which biological data and blood serum concentration data are assumed to follow a log normal distribution and contrasts those principles compared to a model that describes in vitro delivered dose.
Pharmacokinetic (PK) data analysis is based on drug concentration in biological fluid over time (30) . Pharmacokinetic parameters like Cmax, Cmin, Tmax, and AUC are either directly observed from the original drug concentration curve or derived by mathematical calculations (31) . These data are typically modeled using compartmental models that are representations of the body: one-compartment, two-compartment, and multi-compartment models (32) . These compartmental models attempt to describe drug concentrations in the body at the site of action at a particular time point. The concentration is a function, however, of several processes that are related to each other: absorption, distribution, metabolism, and excretion (33) .
Pharmacokinetic equations, based on these compartmental models, are multiplicative. For example, AUC = Clearance − 1 ⋅f⋅dose where f represents the fraction absorbed (31). Clearance can be subject related and therefore, the subject effects are not additive if data are analyzed in the original metric. This compartmental model makes it clear as well that random influences that affect clearance are introduced in a multiplicative manner, not an additive manner. Log transformation of this model results in an equation: Ln(AUC) = − Ln(Clearance) + Ln(f ) + Ln(dose) in which subject effects and variability are now additive effects.
For PK data, to account for this multiplicative effect, the geometric mean rather than the arithmetic mean is the best descriptor (32). Additionally, because there is a lower bound below which the data cannot take on values, the data follows a skewed distribution.
An overall summary of the clinical, pharmacokinetic, and statistical rationale for why bioequivalence parameters are log-transformed was documented by Rani and Pargal (31) . This is, potentially, one reason why the 2001 FDA guidance document does not recommend testing the assumption of log normality for an individual data set. The data are acknowledged to follow a log normal distribution, regardless of output from goodness of fit statistics for a particular data set based on a limited sample size (34).
The section below describes the impact on the hypothesis test and the PBE criterion when the underlying statistical model that describes the data is the normal distribution.
Assessment of Population Bioequivalence Criterion
In its simplest form, the PBE metric, θ, the scaled aggregate criterion in the FDA 2003 draft guidance for nasal aerosols and nasal sprays for local action, is defined as:
assuming an underlying statistical model of the form: The PBE metric represents a combination of differences in means and variances, scaled to the reference product variance for data transformed to the natural log scale. This criterion attempts to encompass equivalency of the entire distribution in a single metric. Equivalency is met if this function of the population parameters is less than an upper acceptance limit, θ BE , or if the linearized criterion, ξ, as shown below, is less than 0.
For a particular data assessment, population equivalency is concluded if the upper 95% confidence bound on the linearized criterion is less than 0. Guidance exists for how to calculate that upper confidence bound (6) .
Values of the upper limit for θ BE are determined based on assumed values for the means and variances from the populations. The acceptance limit stated in the productspecific budesonide guidance allows a 10% shift in the mean and a doubling of the variance in the test population for specific parameter values. This is based on the means of the test and reference populations shifting from 100% to 90% and the variance, in the log-transformed scale, increasing from 0.01 to 0.02. For those given parameter values, a PBE parameter value below 2.089 define the region of equivalency and a value above 2.089 represents non-equivalency. The value of 2.089 is derived from: Using this as the definition of equivalency, the hypothesis statements are the following:
assuming log normality of the data. If, however, the true underlying statistical model is normally distributed, then the model above is not the correct underlying model. The model based on the normal distribution is given below:
where η ij ∼N(0,δ Ti 2 ) i T for the test product, R for the reference product j 1, 2, ⋯,n i α i is the mean of the population (i = T or R) in the original scale δ Ti 2 is the variance of the population (i = T or R) in the original scale Using the Delta method (which is based on a first-order Taylor series expansion), the mean and variance, approximately, of the population when log transformed can be expressed, in the original parameters, as:
ð3:7Þ
This means that the PBE criterion value, in terms of the original parameters that generated the data, is approximately equal to this function:
This is a complex function of population parameters for defining and visualizing equivalency between two populations.
To better understand the parameter space of the PBE criterion (θ) as a function of the original unit parameters (the mean and variance of the test and reference products, α T , α R , δ TT 2 , δ TR 2 ), the PBE parameter value was approximated, based on the first-order Taylor series expansion above, and calculated for a range of values for the population mean and variance, stated in terms of the original data metric, and percent label claim. These values were chosen to represent a range of possible population values for delivered dose. The reference product values encompass parameter values used in simulations from the IPAC-RS database (29) . The test product values were chosen to encompass values less than, equal to, and greater than the reference product. Table I shows the parameter ranges studied.
Results of this analysis, along with output from the simulation study, are presented in the next section.
RESULTS
In this section, results from the assessment of the PBE parameter in the original parameter space as well as results from simulation work are presented and discussed.
Assessment of Population Bioequivalence Criterion in Original Parameters
Graphical output of the PBE parameter value from the combinations listed in Table I is presented in Figs. 2 and 3 . The x-axis is the test product mean value. The y-axis is the PBE population criterion value, approximated, based on Eq. (3.8). The solid red vertical line represents the mean of both 
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PBE population bioequivalence method the test and reference product where no difference exists between populations; the inner, first set of dotted lines represents test product means 10% different (absolute) than the reference product mean. The outer, second set of dotted lines represents test product means 15% different (absolute). The different curves represent varying test product standard deviations, and the boundary of equivalency is shown on the vertical axis as a horizontal black line at the value of 2.089. These plots show how parameter values in the original metric for delivered dose for the mean and variance, approximately, map into the parameter space for the PBE criterion based on the log transformation. These plots highlight the following:
& The PBE parameter value is asymmetric for dose parameter values in the original scale. This means that test product means that are lower than reference product means result in higher PBE values and are, therefore, defined as less equivalent than test product means that are greater than the reference mean by the same amount. As an example, for the case when the reference product mean is 100% label claim (LC) with a standard deviation of 4% and the variance is equal between products, the PBE parameter value is equal to 2.70 for a test product that delivers, on average, 15% lower dose, but is equal to 1.91 for a test product that delivers, on average, 15% more. This is partially due to the non-linear nature of the log transformation. The log transformation will decrease the range of larger values and increase the range of smaller values. This means a difference of +10% is more likely to pass equivalence compared to a difference of −10%.
& This asymmetry is more pronounced as the mean delivered dose values decreased. Test product means 10% lower than reference product means will be less likely to pass equivalence as the reference product mean decreases. Ideally, an absolute difference from target should have the same chance of being declared equivalent and should not depend on the reference product parameter value.
& As the test product variability increased, the PBE parameter value increased, ensuring that the parameter space in which the test product is more variable than the reference product is more likely to result in a conclusion of non-equivalence. In this way, the parameter is behaving as desired.
& If the variance between the test and reference product remained equal but the reference product became more variable, the PBE parameter value changed but the direction of the change depended on whether the test product delivered a higher dose or a lower dose compared to the reference product (see Table II ). For situations in which the test product delivered a lower mean dose than the reference product, the PBE parameter value increased, making equivalence more difficult to declare as variation increased. However, if the test product mean was greater compared to the reference product mean dose, the PBE parameter value decreased for a more variable product, making equivalence more likely to be declared. Ideally, the equivalency metric should be consistent and should not depend on whether the test product mean is higher or lower than the reference product mean.
Simulation Study
To gain a better understanding of this practically, a simulation study was conducted, based on a sample size of n=30. The mean of the reference product was taken to be 90%, 100%, and 110% of label claim. The mean of the test product varied from a difference of −14%, −12%, −10%, −8%, 0%, +8%, +10%, +12%, +14% of label claim compared to the reference product mean and the variance of the test product was taken to be equal to the variance of the reference product and 1.5 times the variance of the reference product for the case in which the reference product standard deviation was 5%. 
Mean Reference Product=90%
Mean Reference Product=100%
Mean Reference Product=110% The simulations were based on 5,000 replicates. From the simulated data, the 95% upper confidence bound of the linearized criterion was calculated following the procedure stated in the draft product-specific budesonide guidance (6) .
A plot of the 95% upper confidence bound of the linearized criterion as a function of the difference between the test product mean and reference product mean in the original scale appears above in Fig. 4 . A quadratic function was fit to the results to visualize the average linearized upper confidence bound value as a function of the test product standard deviation.
As expected, the asymmetry noted in the PBE population parameter from Figs. 2 and 3 is reflected in the increased mean and variability of the upper 95% confidence bound for cases in which the test mean is less than the reference mean. The average upper confidence bound value increases for a more variable test product, meaning equivalence is less likely.
The statistical power of this approach, from the simulations, is presented in Fig. 5 . The observed proportion of simulations in which equivalence was declared is plotted as a function of the difference between the test product and reference product mean in the original scale. The different curves represent varying combinations of reference product mean values and test product standard deviation values when the reference product standard deviation is 5%.
This plot highlights that the statistical power of the PBE approach is not symmetric for a fixed difference between the test product mean and the reference product mean. The probability of declaring equivalency is greater if the test product mean is higher than the reference product mean for the same distance away from the reference product.
Specifically, if the reference product mean is at 100% label claim, then, a test product with the same variation whose mean is 110% is estimated to be declared equivalent 99.18% of the time compared to 79.36% of the time if the test product mean is 90% so a difference in statistical power of almost 20% for the same absolute difference, given no change in variability in the test product. The difference in statistical power becomes greater as the reference product mean decreases to 90%. A test product mean at 100% for products with the same variability, is expected to pass equivalency 89.74% of the time compared to 40.36% of the time if the test product mean was 80% for a difference in statistical power of almost 50% for the same absolute difference that the test product is from the reference product. One would like an equivalency procedure that avoids this lack of symmetry when errors are normally distributed.
CONCLUSIONS
In this paper, fundamental principles for an assumed statistical model were presented for in vitro delivered dose. These principles should be key when implementing statistical methodology for data assessment and decision making. The discrepancy that exists between the development of appropriate statistical models and methodologies for PK data compared to in vitro data was highlighted, and the practical impact on equivalency decisions for in vitro delivered dose, based on applying the PBE statistical approach, was reported. If data are expected to follow a normal distribution, as is the case for in vitro delivered dose, then, decisions using the PBE approach are not consistent for the same absolute mean difference that the test product is from the reference product. A conclusion of inequivalency will occur more often if the test product dose is lower than the reference product for the same deviation from target and this discrepancy in the conclusion grows as the reference product mean decreases. This is due to applying a non-linear log transformation to data that do not follow a log normal distribution. These features of the PBE methodology applied to in vitro delivered dose data, as summarized in this paper, suggest that further research for assessing equivalence is still warranted for in vitro data. In particular, it may not be appropriate to take the logarithm of the data. Those approaches will be further outlined and explored in a subsequent paper.
